Loading institutional data...
Loading institutional data...
No institutional (13F) filings cover this company, so the Overview and 13F tabs are thin. Everything drawn from its SEC filings is here.
Loading snapshot...
Loading financials...
Loading valuation...
Loading analysis...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow on any basis, so a reverse DCF can't be run.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$4.7M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest.
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
Ranked against 16 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-09-30.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMRN | $509M | — | — | 2.4× | -6.5% | 56.6% | -18.2% | -8.4% | -8.4% | — | 9 |
| GYRE | $484M | 228.0× | 31.1× | 4.2× | 10.2% | 95.4% | 8.5% | 15.8% | 15.8% | -3.5× | 7 |
| SVA | $465M | — | — | 1.2× | 6.8% | 67.9% | -51.5% | -4.5% | -4.0% | — | 2 |
| CRMD | $447M | 2.8× | 2.0× | 1.4× | 617% | 88.5% | 52.3% | 40.2% | 40.2% | -1.0× | 24 |
| VREOF | $385M | — | 18.8× | 1.4× | 170% | 47.3% | -25.3% | -22.2% | -22.2% | -6.8× | — |
| EBS | $349M | 7.3× | 3.6× | 0.5× | -28.8% | 56.1% | 7.1% | 10.1% | 4.8% | 1.9× | 29 |
| QTTB | $265M | 3.7× | 12.6× | 4.9× | — | — | 55.5% | 71.0% | 71.0% | -2.8× | 3 |
| ELTP | $248M | 7.7× | 4.3× | 1.7× | 77.1% | 50.4% | 30.1% | 45.4% | 45.4% | -0.6× | — |
| SIGA | $218M | 9.5× | 2.6× | 2.3× | -31.8% | 68.6% | 24.6% | 11.7% | 11.7% | -6.4× | 25 |
| PYXS | $216M | — | — | 15.6× | -14.2% | 82.8% | -575% | -149% | -149% | — | 10 |
| NATR | $216M | 11.6× | 3.1× | 0.5× | 5.7% | 72.4% | 4.1% | 12.1% | 12.1% | -2.4× | 19 |
| AKBA | $196M | — | 2.4× | 0.8× | 47.5% | 83.3% | -2.3% | -16.4% | -6.6% | -5.5× | 27 |
| WHWK | $185M | — | — | 25.9× | -72.5% | 89.4% | -288% | -15.1% | -15.1% | — | 10 |
| MGNX | $153M | — | — | 1.0× | -0.3% | 100% | -49.9% | -134% | -134% | — | 18 |
| DERM | $146M | — | — | 2.4× | 10.2% | 66.2% | -18.5% | -35.9% | -20.0% | — | 4 |
| BGM | $127M | — | — | 3.4× | 51.1% | 16.6% | -52.6% | -5.1% | -5.1% | — | — |
| SILO | $3M | — | — | 37.6× | 0.0% | 38.6% | — | -67.0% | -67.0% | — | — |
Peers = companies sharing SILO's sector (Pharmaceutical Preparations) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
EOD close · as of 2026-10-30
How a revenue dollar becomes profit — FY2025
Dividends and buybacks are cash paid out, shown here against the same year's profit for scale — not funded from it.
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $72K 100.0% | $72K 100.0% | $72K 100.0% | $72K 100.0% | — | $41K 100.0% | $41K 100.0% | — | — | — |
| Cost of Revenue | $44K 61.4% | $6K 8.1% | $6K 8.1% | $6K 8.1% | $5K | $176K 430.4% | $27K 67.5% | — | — | — |
| Gross Profit | $28K 38.6% | $66K 91.9% | $66K 91.9% | $66K 91.9% | $66K | -$135K -330.4% | $13K 32.5% | — | — | — |
| Research & Development | $2.2M 2996.9% | $2.4M 3284.5% | $845K 1172.1% | $1.3M 1784.2% | $694K | $26K 64.1% | — | — | — | — |
| Selling, General & Admin | — | — | $390K 541.0% | $227K 315.2% | $163K | $50K 122.6% | $87K 214.5% | $76K | $30K | $10K |
| Total Operating Expenses | $4.3M 5975.5% | $4.8M 6618.3% | $3.9M 5439.3% | $3.7M 5123.2% | $2.8M | $2.2M 5380.2% | $944K 2325.9% | $594K | $491K | $73K |
| Operating Income | -$4.3M -5937.0% | -$4.7M -6526.4% | -$3.9M -5347.4% | -$3.6M -5031.3% | -$2.7M | -$2.2M -5380.2% | -$930K -2293.4% | -$594K | -$491K | — |
| Interest Expense | $37K 51.7% | $5K 7.1% | $5K 6.8% | $2K 3.0% | $3K | $80 0.2% | $0 0.0% | — | — | — |
| Interest & Investment Income | $207 0.3% | — | — | — | $1K | $12K 28.2% | — | — | — | $625 |
| Other Income (Expense), net | $53K 73.5% | $313K 433.8% | $225K 311.4% | -$280K -388.0% | $6.9M | -$465K -1135.2% | -$83K -204.3% | -$375K | $847K | — |
| Pretax Income | -$4.2M -5863.5% | -$4.4M -6092.6% | -$3.6M -5036.0% | -$3.9M -5419.3% | $4.2M | -$2.7M -6515.3% | — | — | — | — |
| Income Tax Expense | — | — | — | — | $25K | — | — | — | — | — |
| Net Income | -$4.2M -5863.5% | -$4.4M -6092.6% | -$3.7M -5132.6% | -$3.9M -5420.9% | $3.9M | -$3.0M -7422.5% | -$1.0M -2497.7% | -$969K | $357K | — |
| Per Share | ||||||||||
| EPS (Basic) | -$0.50 | -$1.19 | -$1.20 | — | $0.04 | -$0.05 | — | -$0.02 | $0.01 | — |
| EPS (Diluted) | -$0.50 | -$1.19 | -$1.20 | — | $0.04 | -$0.05 | — | -$0.02 | $0.01 | — |
| Weighted Avg Shares (Basic) | 8.4M | 3.7M | 3.1M | 2.3M | 1.9M | 66.0M | — | — | — | 32.4M |
| Weighted Avg Shares (Diluted) | 8.4M | 3.7M | 3.1M | 2.3M | 1.9M | 66.0M | — | 49.1M | 52.1M | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-10-30
Where each multiple sits in its own 5-yr range · 0th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 5-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
ROE -67% against ROIC -67% — 0% of the return on equity comes from leverage and buybacks rather than from the operating business.
Equity is the year-end figure. On average equity over the two year-ends, ROE is -74.6% — the two diverge when buybacks or issuance move equity during the year.
What the company owes vs. what it holds
This shows debt/cash structure and net leverage. The year-by-year maturity schedule is on the Debt & Leverage tab.
Latest year: profit growth vs revenue growth
Operating leverage needs meaningful revenue change.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | — | 67.5 | 430.4 | — | 8.1 | 8.1 | 8.1 | 61.4 |
| Gross Profit | — | 32.5 | -330.4 | — | 91.9 | 91.9 | 91.9 | 38.6 |
| R&D | — | — | 64.1 | — | 1784.2 | 1172.1 | 3284.5 | 2996.9 |
| SG&A | — | 214.5 | 122.6 | — | 315.2 | 541.0 | — | — |
| Operating Income | — | -2293.4 | -5380.2 | — | -5031.3 | -5347.4 | -6526.4 | -5937.0 |
| Net Income | — | -2497.7 | -7422.5 | — | -5420.9 | -5132.6 | -6092.6 | -5863.5 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on SILO: price, valuation and headline fundamentals from SEC filings. The four questions at the top of the page are where the judgements live.
No positive operating income in the last three years, so there is no return on capital to compare against its cost.
| Fiscal year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY2019 | 32.5% | -2293.4% | -2497.7% |
| FY2020 | -330.4% | -5380.2% | -7422.5% |
| FY2022 | 91.9% | -5031.3% | -5420.9% |
| FY2023 | 91.9% | -5347.4% | -5132.6% |
| FY2024 | 91.9% | -6526.4% | -6092.6% |
| FY2025 | 38.6% | -5937.0% | -5863.5% |
Return on equity (-67%) and return on invested capital (-67%) are within a couple of points in FY2025, so the headline return is the operating return — there is no meaningful leverage effect to strip out.
No material counter-signal in the checked set: ROIC vs WACC spread, 5-year spread history, gross margin trend, operating margin trend, net margin against 3 years ago, revenue growth, ROIC ex-goodwill gap.
Missing from our data, so excluded from this answer: positive EBIT.
Fewer than three profitable years with a cash flow statement, so cash conversion cannot be judged.
No material counter-signal in the checked set: FCF / net income over 3 and 5 years, Sloan accruals, SBC as a share of revenue, SBC as a share of operating cash flow, SBC-adjusted free cash flow, free cash flow per diluted share, buybacks against SBC issued, capex vs depreciation, free cash flow against revenue, share count since the first year on file, cash conversion cycle (DSO, DIO, DPO), receivables growth against revenue growth.
Missing from our data, so excluded from this answer: 3 years of cash flow.
No debt, so there is no leverage path to distress.
Balance sheet at 2025-12-31. Undrawn revolving credit is not shown: the tag is collected but not yet mapped through to the API.
Cash burn, not leverage, is the risk for a debt-free company — see question 2 for cash conversion.
No positive free cash flow to discount, so the price cannot be expressed as a growth requirement.
The percentile ranks the FISCAL-YEAR point, because the distribution behind each strip is built from fiscal-year closes — ranking a TTM figure inside it would compare two different bases. TTM basis: TTM.
No material counter-signal in the checked set: reverse-DCF implied growth, historical FCF CAGR, per-year FCF growth distribution, reporting-basis breaks, discount rate used, free-cash-flow basis (stock comp charged?).
Missing from our data, so excluded from this answer: free_cash_flow.